3 Questions: Cullen Buie on a new era for cell therapies
The associate professor of MechE reflects on how his company, Kytopen, has grown and shifted focus in developing safer immunotherapies.
The associate professor of MechE reflects on how his company, Kytopen, has grown and shifted focus in developing safer immunotherapies.
Stacy Springs named executive director; Richard Braatz is associate faculty director.
Jonathan Weissman and collaborators used their single-cell sequencing tool Perturb-seq on every expressed gene in the human genome, linking each to its job in the cell.
MIT neuroscientists expand CRISPR toolkit with new, compact Cas7-11 enzyme.
Exploring diversity among bacterial immune systems, McGovern Institute scientists uncovere a programmable system for precisely targeting and modifying RNA.
Researchers find RNA-guided enzymes are more diverse and widespread than previously believed.
Novel method, developed by McGovern Institute researchers, may lead to safer, more efficient gene therapies.
New, reversible CRISPR method can control gene expression while leaving underlying DNA sequence unchanged.
Collaborative research center funded by Lisa Yang and Hock Tan ’75 blends engineering and neuroscience to advance molecular tools for treating brain disorders.
Voigt Lab's work could eventually replace cereal crops’ need for nitrogen from chemical fertilizers.
Selecta Bioscience’s ImmTOR platform could improve gene therapies and prevent some drug side effects.
Researchers are developing a so-called "daisy-chain" gene-drive system that provides controls for genetic engineering of certain populations.
Associate professor of chemical engineering talks about the future of biochemistry and the next generation of scientists and engineers.
New MIT technique could help decipher genes’ roles in learning and memory.